INO Stock News: Inovio Pharmaceuticals Inc. rallies as investors buy the dip
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NASDAQ:INO rebounded on Thursday as the stock rose by 7.05%.
- Inovio still awaits resumption of Phase 2/3 clinical trials for INO-4800.
- Gilead vaccine candidate has been the first COVID-19 treatment approved by the FDA.
NASDAQ:INO has fallen far enough according to investors as bargain hunters flocked back to the biotech firm on Thursday, pumping the stock price up by 7.05% to close the trading session at $11.24. While no real news emerged to warrant the spike, it should be noted that the broader markets rebounded after mixed results for most of the week. Despite the gains made on Thursday, shares traded at a lower volume than on average for Inovio which signals that a few big trades may have been the source for the price jump, given the higher volatility.
Pharmaceutical giant Gilead Sciences (NASDAQ:GILD) received the first approval from the FDA for its COVID-19 vaccine candidate: remdesivir, also known as Veklury. While the drug previously received EUA or Emergency Use Authorization in May, the FDA has now given full approval as well as amending its EUA for use in pediatric patients. Veklury has been shown to reduce the recovery time of COVID-19 patients on average from 15 days to 10 days. Veklury has now been approved for use in nearly 50 countries around the world, including Australia, Canada, Iran, and Japan.
Inovio Pharmaceuticals stock chart
So is this the end for Inovio in terms of a COVID-19 vaccine? Not necessarily, although the chances of INO-4800 being chosen and distributed are fading by the day. Scientists have said that multiple variations of COVID-19 vaccines will be needed to sufficiently control the spread worldwide so just because Veklury has been chosen now, it does not eliminate other vaccines from being chosen in the future.
- NASDAQ:INO rebounded on Thursday as the stock rose by 7.05%.
- Inovio still awaits resumption of Phase 2/3 clinical trials for INO-4800.
- Gilead vaccine candidate has been the first COVID-19 treatment approved by the FDA.
NASDAQ:INO has fallen far enough according to investors as bargain hunters flocked back to the biotech firm on Thursday, pumping the stock price up by 7.05% to close the trading session at $11.24. While no real news emerged to warrant the spike, it should be noted that the broader markets rebounded after mixed results for most of the week. Despite the gains made on Thursday, shares traded at a lower volume than on average for Inovio which signals that a few big trades may have been the source for the price jump, given the higher volatility.
Pharmaceutical giant Gilead Sciences (NASDAQ:GILD) received the first approval from the FDA for its COVID-19 vaccine candidate: remdesivir, also known as Veklury. While the drug previously received EUA or Emergency Use Authorization in May, the FDA has now given full approval as well as amending its EUA for use in pediatric patients. Veklury has been shown to reduce the recovery time of COVID-19 patients on average from 15 days to 10 days. Veklury has now been approved for use in nearly 50 countries around the world, including Australia, Canada, Iran, and Japan.
Inovio Pharmaceuticals stock chart
So is this the end for Inovio in terms of a COVID-19 vaccine? Not necessarily, although the chances of INO-4800 being chosen and distributed are fading by the day. Scientists have said that multiple variations of COVID-19 vaccines will be needed to sufficiently control the spread worldwide so just because Veklury has been chosen now, it does not eliminate other vaccines from being chosen in the future.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.